Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.50 (23.76% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetDetailsShare
2/18/2015WedbushInitiated CoverageBuy$13.00ViewTweet This Rating  Share This Rating on StockTwits
10/6/2014Leerink SwannInitiated CoverageOutperform$12.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013WedbushDowngradeOutperform -> Neutral$1.20ViewTweet This Rating  Share This Rating on StockTwits
11/11/2013OppenheimerDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
3/7/2013MLV & Co Boost Price TargetHold$0.50 -> $0.75ViewTweet This Rating  Share This Rating on StockTwits
3/6/2013OppenheimerReiterated RatingOutperform$2.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 2/27/2013 forward)